To include your compound in the COVID-19 Resource Center, submit it here.

More is less in CNS

Running clinical trials can be complicated when some of the disease symptoms a compound is designed to treat are also side effects of the compound. MediciNova Inc. ran into just such a conundrum with its serotonin (5-HT1A) receptor agonist, which it is developing to treat generalized anxiety disorder.

Last week, the company reported that MN-305 missed the primary endpoint in a Phase II/III trial. The

Read the full 656 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE